Benitec Biopharma Inc.(BNTC)

NASDAQ Capital Market

Sector: Healthcare | Industry: Biotechnology

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Latest News & Analysis

Benitec Biopharma (BNTC) stock analysis: Clinical trial progress, financial health, and market outlook for BB-301 OPMD treatment. Stay informed on gene therapy advancements.

Feb 21, 2025

Benitec Biopharma (BNTC): BB-301 Clinical Trial Update and OPMD Gene Therapy Progress

Benitec Biopharma (BNTC) navigates clinical trials and market dynamics. Analysts predict upside amidst financial results and RNAi therapy advancements.